Garen Bohlin
Director/Board Member at COLLEGIUM PHARMACEUTICAL, INC.
Net worth: 155 623 $ as of 2024-03-30
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Michael Heffernan | M | 59 | 22 years | |
John Freund | M | 70 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 17 years |
Joseph Ciaffoni | M | 53 | 7 years | |
Richard Paulson | M | 56 | 4 years | |
Mike Mason | M | 49 |
Praecis Pharmaceuticals, Inc.
Praecis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Praecis Pharmaceuticals, Inc. develops drugs and therapies for the treatment of cancer. The firm also develops peptide-based drugs. The company was founded 1993 and is headquartered in Waltham, MA. | 11 years |
Shirley Kuhlmann | F | 40 | 6 years | |
Sohanya Cheng | F | 41 | 3 years | |
Neil McFarlane | M | 51 | 2 years | |
Gino Santini | M | 66 | 12 years | |
Christy Oliger | F | 54 | 4 years | |
Mansoor Mirza | M | 63 | 14 years | |
Brenda J. Sousa | F | 60 | 14 years | |
Rita Balice-Gordon | M | 63 | 4 years | |
Accumanno James | M | - | 3 years | |
Michael Mano | M | 47 | 4 years | |
John Fallon | M | 76 | 8 years | |
Chen Schor | M | 51 | 4 years | |
Scott Dreyer | M | 52 | 6 years | |
Deepa Pakianathan | M | 59 | 11 years | |
Su Zhen | M | 47 | 1 years | |
Gwen Melincoff | M | 72 | 7 years | |
Barry Greene | M | 60 | 11 years | |
Scott Sudduth | M | - | 6 years | |
Kelly Clements | F | - | 2 years | |
William I. Ramage | M | - | 11 years | |
Stuart Poulton | M | 51 | 2 years | |
Christopher James | M | - | 1 years | |
Marissa Samuels | F | - | 2 years | |
Lisa DiPaolo | F | - | 2 years | |
Brian Austad | M | - | 11 years | |
Reshma Rangwala | M | 46 | 2 years | |
Colleen Tupper | F | 48 | 3 years | |
Arun Padmanabhan | M | - | 7 years | |
Elhan Webb | F | - | 2 years | |
Thomas Smith | M | 63 | 2 years | |
Bart J. Dunn | M | 65 | 5 years | |
Craig Johnson | M | 62 | 4 years | |
Kevin Tang | M | 57 | 4 years | |
Amama Sadiq | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Paul Brannelly | M | 51 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 13 years |
Larry G. Edwards | M | 52 | 5 years | |
Sharon Shacham | M | 53 | 13 years | |
Leonard Patrick Gage | M | 81 |
Genetics Institute LLC
Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | 19 years |
Kevin McLaughlin | M | 67 |
Praecis Pharmaceuticals, Inc.
Praecis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Praecis Pharmaceuticals, Inc. develops drugs and therapies for the treatment of cancer. The firm also develops peptide-based drugs. The company was founded 1993 and is headquartered in Waltham, MA. | 11 years |
Malcolm L. Gefter | M | - |
Praecis Pharmaceuticals, Inc.
Praecis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Praecis Pharmaceuticals, Inc. develops drugs and therapies for the treatment of cancer. The firm also develops peptide-based drugs. The company was founded 1993 and is headquartered in Waltham, MA. | 14 years |
John Thero | M | 63 | 4 years | |
Keith E. Dionne | M | - | - | |
Rick Gyory | M | - |
SpringLeaf Therapeutics, Inc.
SpringLeaf Therapeutics, Inc. Drugstore ChainsRetail Trade SpringLeaf Therapeutics, Inc. is creating innovative therapeutic modalities to address serious disease and elevate the quality of care for patients. SpringLeaf's technology is based on the convergence of materials science and medicine and is designed to enable and differentiate therapeutics. SpringLeaf was founded based on breakthrough science at MIT and is backed by leading investors including Excel Venture Management, Flybridge Capital Partners, North Bridge Venture Partners and SR One. | 7 years |
James E. Audia | M | 68 | 10 years | |
Lawrence G. Miller | M | 70 | 7 years | |
Mark Levin | M | 73 | - | |
Mark Leuchtenberger | M | 67 | 2 years | |
Guy MacDonald | M | 65 | 11 years | |
Michael J. Todisco | M | 59 | - | |
Pieter Muntendam | M | 65 |
SpringLeaf Therapeutics, Inc.
SpringLeaf Therapeutics, Inc. Drugstore ChainsRetail Trade SpringLeaf Therapeutics, Inc. is creating innovative therapeutic modalities to address serious disease and elevate the quality of care for patients. SpringLeaf's technology is based on the convergence of materials science and medicine and is designed to enable and differentiate therapeutics. SpringLeaf was founded based on breakthrough science at MIT and is backed by leading investors including Excel Venture Management, Flybridge Capital Partners, North Bridge Venture Partners and SR One. | - |
Lawrence A. Gyenes | M | 73 | 2 years | |
Cameron Peters | M | 64 | - | |
Michael Kauffman | M | 60 | 14 years | |
Daniel Char | M | 63 |
Targanta Therapeutics Corp.
Targanta Therapeutics Corp. BiotechnologyHealth Technology Targanta Therapeutics Corp. discovers and develops novel antibacterial pro drugs. The company was founded in 1997 and is headquartered in Parsippany, NJ. | 1 years |
Mona L. Haynes | F | 66 |
Targanta Therapeutics Corp.
Targanta Therapeutics Corp. BiotechnologyHealth Technology Targanta Therapeutics Corp. discovers and develops novel antibacterial pro drugs. The company was founded in 1997 and is headquartered in Parsippany, NJ. | 2 years |
Mikael Dolsten | M | 65 | 6 years | |
Steve Gullans | M | 71 | 5 years | |
David Gamsey | M | 66 |
Arthur Andersen LLP
Arthur Andersen LLP Miscellaneous Commercial ServicesCommercial Services Arthur Andersen LLP used to provide accounting services. It was also into consulting services for clients that operate businesses throughout the United States and around the world. Arthur Andersen was founded in 1913 and was headquartered in Chicago, IL. | 8 years |
Larry Tsai | M | 52 | 5 years | |
Peter Honig | M | 67 | 2 years | |
Maria D. Stahl | F | 53 | 5 years | |
Alison B. Fleming | M | 49 | 19 years | |
Eran Nadav | M | 55 | - | |
Ernest A. Kopecky | M | 57 | 5 years | |
Ian Karp | M | - | - | |
Jatin Shah | M | 49 | 5 years | |
Raimonds Dzelme | M | - | - | |
Michael DeGeorge | M | - | 7 years | |
Paula Rusu | F | - | 5 years | |
Lisa Meletta | F | - | - | |
Gail Steinel | F | 67 |
Arthur Andersen LLP
Arthur Andersen LLP Miscellaneous Commercial ServicesCommercial Services Arthur Andersen LLP used to provide accounting services. It was also into consulting services for clients that operate businesses throughout the United States and around the world. Arthur Andersen was founded in 1913 and was headquartered in Chicago, IL. | 25 years |
Michael Cima | M | 64 |
SpringLeaf Therapeutics, Inc.
SpringLeaf Therapeutics, Inc. Drugstore ChainsRetail Trade SpringLeaf Therapeutics, Inc. is creating innovative therapeutic modalities to address serious disease and elevate the quality of care for patients. SpringLeaf's technology is based on the convergence of materials science and medicine and is designed to enable and differentiate therapeutics. SpringLeaf was founded based on breakthrough science at MIT and is backed by leading investors including Excel Venture Management, Flybridge Capital Partners, North Bridge Venture Partners and SR One. | 7 years |
Richard S. Blumberg | M | - |
Bioverativ Therapeutics, Inc.
Bioverativ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bioverativ Therapeutics, Inc. develops pharmaceutical products. It develops medicines for chronic diseases such as hemophilia, anemia, multiple sclerosis, and autoimmune disorders. The company is headquartered in Cambridge, MA. | - |
Marc B. Garnick | M | - |
Praecis Pharmaceuticals, Inc.
Praecis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Praecis Pharmaceuticals, Inc. develops drugs and therapies for the treatment of cancer. The firm also develops peptide-based drugs. The company was founded 1993 and is headquartered in Waltham, MA. | - |
Thomas White | M | 66 |
Arthur Andersen LLP
Arthur Andersen LLP Miscellaneous Commercial ServicesCommercial Services Arthur Andersen LLP used to provide accounting services. It was also into consulting services for clients that operate businesses throughout the United States and around the world. Arthur Andersen was founded in 1913 and was headquartered in Chicago, IL. | - |
Michael Falvey | M | 65 | 2 years | |
Nancy Wysenski | F | 66 | 6 years | |
Allen Robert McGee | M | 73 |
Arthur Andersen LLP
Arthur Andersen LLP Miscellaneous Commercial ServicesCommercial Services Arthur Andersen LLP used to provide accounting services. It was also into consulting services for clients that operate businesses throughout the United States and around the world. Arthur Andersen was founded in 1913 and was headquartered in Chicago, IL. | - |
Justin Renz | M | 52 | 3 years | |
J. Garland | M | 55 | 6 years | |
Chris Primiano | M | 44 | 6 years | |
Richard Pops | M | 62 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 4 years |
Richard H. Aldrich | M | 69 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | 4 years |
Douglas Cole | M | 63 | 7 years | |
Robert Moccia | M | 66 |
PreCision Dermatology, Inc.
PreCision Dermatology, Inc. Pharmaceuticals: MajorHealth Technology PreCision Dermatology, Inc. developed skincare therapies. It offered pharmaceutical products for skin barrier restoration, dermatoses, rosacea, acne, seborrheic dermatitis, and scaling associated with hyperkeratotic skin. The company was founded by Jeffrey M. Nugent in 2010 and was headquartered in Cumberland, RI. | - |
Robert Mark Weisskoff | M | 61 | 6 years | |
Laurence J. Blumberg | M | 62 |
Bioverativ Therapeutics, Inc.
Bioverativ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bioverativ Therapeutics, Inc. develops pharmaceutical products. It develops medicines for chronic diseases such as hemophilia, anemia, multiple sclerosis, and autoimmune disorders. The company is headquartered in Cambridge, MA. | - |
Patrick Heron | M | 53 | 8 years | |
Karl D. Handelsman | M | 63 | 7 years | |
David Lubner | M | 60 | 10 years | |
Gerri Henwood | F | 71 | 5 years | |
Theodore Schroeder | M | 69 | 5 years | |
Mike Scharf | M | 76 |
Arthur Andersen LLP
Arthur Andersen LLP Miscellaneous Commercial ServicesCommercial Services Arthur Andersen LLP used to provide accounting services. It was also into consulting services for clients that operate businesses throughout the United States and around the world. Arthur Andersen was founded in 1913 and was headquartered in Chicago, IL. | 9 years |
Eric M. Gordon | M | 78 |
Targanta Therapeutics Corp.
Targanta Therapeutics Corp. BiotechnologyHealth Technology Targanta Therapeutics Corp. discovers and develops novel antibacterial pro drugs. The company was founded in 1997 and is headquartered in Parsippany, NJ. | 2 years |
Marlo Manning | F | - | - |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Garen Bohlin
- Personal Network